These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20038361)

  • 1. [Skin manifestations of toxic syndrome due to denatured rapeseed oil].
    Fonseca E
    Actas Dermosifiliogr; 2009 Dec; 100(10):857-60. PubMed ID: 20038361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxic oil syndrome: the perspective after 20 years.
    Posada de la Paz M; Philen RM; Borda AI
    Epidemiol Rev; 2001; 23(2):231-47. PubMed ID: 12192735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome.
    Kilbourne EM; Posada de la Paz M; Abaitua Borda I; Diez Ruiz-Navarro M; Philen RM; Falk H
    J Am Coll Cardiol; 1991 Sep; 18(3):711-7. PubMed ID: 1869734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous mucinosis in the toxic oil syndrome.
    Fonseca E; Contreras F
    J Am Acad Dermatol; 1987 Jan; 16(1 Pt 1):139-40. PubMed ID: 3805384
    [No Abstract]   [Full Text] [Related]  

  • 5. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1993 Nov; 5(6):802-8. PubMed ID: 8117543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Silver RM
    Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the alimentary toxic oil syndrome due to ingestion of denatured rapeseed oil.
    Gilsanz V; Alvarez JL; Serrano S; Simón J
    Arch Intern Med; 1984 Feb; 144(2):254-6. PubMed ID: 6696559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
    Bolster MB; Silver RM
    Curr Opin Rheumatol; 1994 Nov; 6(6):642-9. PubMed ID: 7865387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous toxic mucinoses.
    Rongioletti F; Rebora A
    J Am Acad Dermatol; 1992 May; 26(5 Pt 1):789-90. PubMed ID: 1583189
    [No Abstract]   [Full Text] [Related]  

  • 10. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.
    Alonso-Ruiz A; Calabozo M; Perez-Ruiz F; Mancebo L
    Medicine (Baltimore); 1993 Sep; 72(5):285-95. PubMed ID: 8412642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eosinophilia-myalgia: new syndrome].
    Szechiński J; Borysewicz K
    Postepy Hig Med Dosw; 1992; 46(3):319-25. PubMed ID: 1369828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic oil syndrome: traceback of the toxic oil and evidence for a point source epidemic.
    Posada de la Paz M; Philen RM; Borda IA; Sicilia Socias JM; Gómez de la Cámara A; Kilbourne EM
    Food Chem Toxicol; 1996 Mar; 34(3):251-7. PubMed ID: 8621106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
    Maitani T; Saitoh H
    Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
    [No Abstract]   [Full Text] [Related]  

  • 15. [Toxic oil syndrome--an example of an exogenously-induced autoimmune disease].
    Bell S; Brand K; Meurer M
    Hautarzt; 1992 Jun; 43(6):339-43. PubMed ID: 1628965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
    Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
    Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels.
    Hertzman PA
    Adv Exp Med Biol; 1996; 398():339-42. PubMed ID: 8906286
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical, pathologic, and immunopathologic manifestations of the toxic oil syndrome. Analysis of fourteen cases.
    Phelps RG; Fleischmajer R
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):313-24. PubMed ID: 3279088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The toxic oil syndrome (TOS, 1981): from the disease towards a toxicological understanding of its chemical aetiology and mechanism.
    Aldridge WN
    Toxicol Lett; 1992 Dec; 64-65 Spec No():59-70. PubMed ID: 1471212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-(Phenylamino)alanine--a link between eosinophilia-myalgia syndrome and toxic oil syndrome?
    Philen RM; Hill RH
    Mayo Clin Proc; 1993 Feb; 68(2):197-200. PubMed ID: 8423703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.